All In MedTech

Device Trial Radar · NCT05313165

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 22, 2022

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
LimFlow, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 6, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

Conditions

  • Critical Limb Ischemia
  • Chronic Limb-Threatening Ischemia
  • Peripheral Arterial Disease

Interventions

  • LimFlow Stent Graft SystemDevice

    Creation of an arteriovenous fistula in the desired limb location

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amputation Free SurvivalTime frame: 6 Months

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego Health

    La Jolla, California · Withdrawn

  • Stanford University School of Medicine

    Palo Alto, California · Completed

  • UCSF

    San Francisco, California · Completed

27 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.